X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense in USD from 2016 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
X4 Pharmaceuticals, Inc quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2016 to Q3 2025.
  • X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the quarter ending September 30, 2025 was $760K, a 58.2% decline year-over-year.
  • X4 Pharmaceuticals, Inc Share-based Payment Arrangement, Expense for the twelve months ending September 30, 2025 was $4.24M, a 50.2% decline year-over-year.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2024 was $8.2M, a 5.56% decline from 2023.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2023 was $8.69M, a 67.1% increase from 2022.
  • X4 Pharmaceuticals, Inc annual Share-based Payment Arrangement, Expense for 2022 was $5.2M, a 15.9% decline from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Growth (%)

X4 Pharmaceuticals, Inc Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $4.24M $760K -$1.06M -58.2% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $5.3M $748K -$1.68M -69.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-08
Q1 2025 $6.98M $519K -$1.22M -70.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-01
Q4 2024 $8.2M $2.22M -$322K -12.7% Oct 1, 2024 Dec 31, 2024 10-K 2025-03-26
Q3 2024 $8.53M $1.82M -$541K -22.9% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $9.07M $2.43M +$286K +13.4% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-08
Q1 2024 $8.78M $1.74M +$94K +5.71% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-01
Q4 2023 $8.69M $2.54M +$1.43M +129% Oct 1, 2023 Dec 31, 2023 10-K 2025-03-26
Q3 2023 $7.26M $2.36M +$1.25M +113% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-13
Q2 2023 $6.01M $2.14M +$620K +40.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 $5.39M $1.65M +$186K +12.7% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q4 2022 $5.2M $1.11M -$502K -31.2% Oct 1, 2022 Dec 31, 2022 10-K 2025-03-26
Q3 2022 $5.7M $1.11M -$405K -26.7% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $6.11M $1.52M -$275K -15.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $6.38M $1.46M +$201K +16% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q4 2021 $6.18M $1.61M +$211K +15.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-21
Q3 2021 $5.97M $1.52M -$728K -32.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $6.7M $1.8M +$624K +53.2% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 $6.07M $1.26M +$645K +105% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-12
Q4 2020 $5.43M $1.4M +$734K +111% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-21
Q3 2020 $4.69M $2.24M +$1.55M +225% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $3.14M $1.17M +$740K +171% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-03
Q1 2020 $2.4M $613K +$351K +134% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.05M $664K +$376K +131% Oct 1, 2019 Dec 31, 2019 10-K 2022-03-17
Q3 2019 $1.67M $691K +$493K +249% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.18M $433K +$288K +199% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-04
Q1 2019 $893K $262K +$134K +105% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $759K $288K +$423K Oct 1, 2018 Dec 31, 2018 10-K 2021-03-19
Q3 2018 $336K $198K -$75K -27.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $411K $145K -$27K -15.7% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $438K $128K -$54K -29.7% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 $492K -$135K Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $273K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $172K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 $182K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-10

X4 Pharmaceuticals, Inc Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $8.2M -$483K -5.56% Jan 1, 2024 Dec 31, 2024 10-K 2025-03-26
2023 $8.69M +$3.49M +67.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-03-26
2022 $5.2M -$981K -15.9% Jan 1, 2022 Dec 31, 2022 10-K 2025-03-26
2021 $6.18M +$752K +13.9% Jan 1, 2021 Dec 31, 2021 10-K 2024-03-21
2020 $5.43M +$3.38M +165% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-21
2019 $2.05M +$1.29M +170% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-17
2018 $759K +$267K +54.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-03-19
2017 $492K -$152K -23.6% Jan 1, 2017 Dec 31, 2017 10-K 2020-03-12
2016 $644K Jan 1, 2016 Dec 31, 2016 10-K 2019-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.